Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Alexander RöthSatoshi IchikawaYoshikazu ItoJin Seok KimZsolt NagyNaoshi ObaraJens Peter PanseHubert SchrezenmeierSimona SicaJuliette SoretKensuke UsukiSung-Soo YoonNadiesh BalachandranMuriel BuriPontus LundbergHimika PatelKenji ShinomiyaAlexandre SostellyJun-Ichi NishimuraPublished in: European journal of haematology (2023)
Over a 3-year median treatment duration, crovalimab was well tolerated and sustained C5 inhibition was achieved. Intravascular haemolysis control, haemoglobin stabilisation and transfusion avoidance were maintained, signifying long-term crovalimab efficacy.